我的生活+的主要目标之一是帮助人们预防新的HIV和其他STI,丙型肝炎和结核病病历的产生。

该应用程序有助于建立医生和HIV感染者之间的匿名沟通。 它可以让您创建简单易行的服药时间表,并设置隐藏和个性化的提醒。

返回
25 九月 2018, 14:04
1866

American patients with hepatitis C will be available branded generics Gilead

American patients with hepatitis C will be available branded generics Gilead - 图片 1

On Monday, September 24, the American biopharmaceutical company Gilead Sciences Inc. said that it expects to launch in the US the production of a number of analogues for its own products. Among the applicants for the release are generic drugs for the treatment of hepatitis C Epclusa (sofosbuvir / velpatasvir) and Harvoni (ledipasvir / sofosbuvir).

Medicines will be produced by the subsidiary structure of Gilead, the company Asegua Therapeutics LLC. As expected, the cost of treatment with new drugs that will appear in the US in 2019, will be $ 24 thousand.

According to the International Coalition for Preparedness for Treatment (ITPCru) with reference to Bloomberg, the decision to launch the production of its own line of generics was made by Gilead after the approval of the FDA of the analogue of Teva's costly EpiPen epinephrine autoinjector.

We add that, according to the representatives of Gilead, while the newest combinations for the treatment of hepatitis C were in market circulation (Harvoni - from 2014, Epclusa - since 2016), their average price for purchases by the state and insurers decreased by almost 60% (at the start of sales $ 94.5 thousand and $ 74.76 thousand per course, respectively).

Nevertheless, the company said, "because of the complexity of the structure of the US healthcare system, these discounts [...] do not always mean a low price for the patient."

在社交媒体上分享